Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Double-blind randomized pilot study of oral lyophilized fecal microbiota transplantation for irritable bowel syndrome
MOH_2024-06-09_013460Phase 2Not yet recruiting
- Sponsor
- חגי בר יוסף
- Start
- May 2024
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of allogeneic fecal microbiota and vancomycin in irritable bowel syndrome (IBS) (2 arms), sponsored by חגי בר יוסף. Planned start May 2024; status: not yet recruiting.
02
Drugs
allogeneic fecal microbiotavancomycin
03
Conditions
irritable bowel syndrome (IBS)
Beyond the preview
Go deeper on MOH_2024-06-09_013460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-06-09_013460.